ICOSLG and neoplasm: As we know, majority of tumors, including MHC+ and MHC− tumors, escape the immune surveillance and killing with multiple mechanisms, such as hiding the tumor-specific antigen (TSA), and/or absence of costimulatory activation ligands, even over-expression immune checkpoint ligands (PD-L1, ICOS-L, OX40L etc.)[14].